HC Wainwright Weighs in on Kezar Life Sciences, Inc.’s FY2024 Earnings (NASDAQ:KZR)

Kezar Life Sciences, Inc. (NASDAQ:KZR – Get Rating) – Analysts at HC Wainwright issued their FY2024 earnings estimates for shares of Kezar Life Sciences in a report issued on Thursday, March 16th. HC Wainwright analyst R. Selvaraju expects that the company will earn ($1.19) per share for the year. HC Wainwright currently has a “Buy” rating and a $21.00 target price on the stock. The consensus estimate for Kezar Life Sciences’ current full-year earnings is ($1.25) per share.

Several other research firms also recently commented on KZR. Wells Fargo & Company reduced their price target on shares of Kezar Life Sciences from $17.00 to $14.00 and set an “overweight” rating for the company in a research report on Tuesday, January 3rd. William Blair reiterated a “market perform” rating on shares of Kezar Life Sciences in a research report on Wednesday.

Kezar Life Sciences Stock Down 1.6 %

KZR stock opened at $3.76 on Friday. The company has a fifty day moving average price of $6.21 and a 200 day moving average price of $7.28. Kezar Life Sciences has a 12 month low of $3.55 and a 12 month high of $18.55. The company has a market cap of $257.11 million, a price-to-earnings ratio of -3.72 and a beta of 0.25. The company has a debt-to-equity ratio of 0.03, a current ratio of 31.15 and a quick ratio of 31.15.

Insiders Place Their Bets

In other Kezar Life Sciences news, major shareholder Morningside Venture Investment sold 5,000 shares of the company’s stock in a transaction on Thursday, January 12th. The shares were sold at an average price of $6.77, for a total transaction of $33,850.00. Following the completion of the transaction, the insider now owns 5,881,078 shares in the company, valued at approximately $39,814,898.06. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In the last quarter, insiders sold 248,276 shares of company stock worth $1,708,683. 7.80% of the stock is owned by insiders.

Hedge Funds Weigh In On Kezar Life Sciences

A number of large investors have recently bought and sold shares of the company. Bayesian Capital Management LP purchased a new position in shares of Kezar Life Sciences in the 3rd quarter valued at about $248,000. ProShare Advisors LLC purchased a new position in shares of Kezar Life Sciences in the 3rd quarter valued at about $100,000. E Fund Management Co. Ltd. purchased a new position in shares of Kezar Life Sciences in the 3rd quarter valued at about $145,000. Trexquant Investment LP increased its holdings in shares of Kezar Life Sciences by 173.8% in the 2nd quarter. Trexquant Investment LP now owns 98,187 shares of the company’s stock valued at $812,000 after purchasing an additional 62,326 shares in the last quarter. Finally, Occudo Quantitative Strategies LP purchased a new position in shares of Kezar Life Sciences in the 2nd quarter valued at about $778,000. Hedge funds and other institutional investors own 84.03% of the company’s stock.

Kezar Life Sciences Company Profile

(Get Rating)

Kezar Life Sciences, Inc is a clinical-stage biopharmaceutical company which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer in South San Francisco and California. Its product pipeline include KZR-616, KZR-261, and KZR-TBD. The company was founded by John Fowler, Christopher J.